RecruitingPhase 1NCT05500807
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Studying Von Willebrand disease type 3
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bleeding and Clotting Disorders Institute Peoria, Illinois
- Principal Investigator
- Jonathan C Roberts, MDBleeding and Clotting Disorders Institute
- Intervention
- Emicizumab(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 0-90 years · All sexes
- Timeline
- 2022 – 2027
Study locations (9)
- The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD), Orange, California, United States
- Stanford University: Stanford Children's Health, Redwood City, California, United States
- University of Miami - Miller School of Medicine, Coral Gables, Florida, United States
- St. Joseph's Children's Hospital - Center for Bleeding and Clotting Disorders, Tampa, Florida, United States
- Bleeding and Clotting Disorders Institute (BCDI), Peoria, Illinois, United States
- Innovative Hematology, Inc. (IHI), Indianapolis, Indiana, United States
- University of Michigan Medical School, Ann Arbor, Michigan, United States
- Central Michigan University: Children's Hospital of Michigan, Mount Pleasant, Michigan, United States
- Washington Center for Bleeding Disorders, Seattle, Washington, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05500807 on ClinicalTrials.gov